Hypothesis

BPC-157 functions as an extracellular matrix‑bound allosteric modulator of the Growth Hormone Secretagogue Receptor (GHSR1a) that enhances growth hormone receptor (GHR) expression and JAK2 signaling in human tendon fibroblasts.

Mechanistic Rationale

1. Heparan sulfate proteoglycan (HSPG) tethering – BPC-157 contains a cluster of basic residues (Arg, Lys) that favor electrostatic binding to heparan sulfate chains on syndecans and glypicans, a motif shared with other fibroblast‑active peptides (e.g., FGF2) 1. This interaction localizes BPC-157 to the pericellular matrix where GHSR resides.
2. Allosteric modulation of GHSR – Binding of BPC-157 to HSPG‑presented GHSR induces a conformational shift that increases the receptor’s basal activity and its sensitivity to endogenous ghrelin, analogous to how heparin potentiates FGF‑FGFR signaling. GHSR activation is known to cross‑talk with the JAK2‑STAT5 pathway via Src family kinases, thereby upregulating GHR transcription 2.
3. Rapid Egr-1 induction – The Src‑dependent phosphorylation of ERK1/2 downstream of GHSR can explain the observed 15‑minute rise in Egr-1 mRNA 3.
4. Nitric oxide modulation – GHSR signaling stimulates eNOS via the PI3K‑Akt pathway, increasing Nos3/Nos1 while suppressing Nos2/Nfkb, matching the NO profile reported for BPC-157 4.
5. Species translation – Human tendon fibroblasts express both syndecan‑4 and GHSR1a at levels comparable to rodent Achilles tendon, providing a plausible conserved mechanism.

Testable Predictions

• If BPC-157’s activity depends on HSPG, enzymatic removal of heparan sulfate (heparinase III) or genetic knockdown of syndecan‑4 will abolish BPC‑157‑induced GHR mRNA upregulation and JAK2 phosphorylation.
• Blocking GHSR with the inverse agonist [D-Lys3]-GHRP‑6 will prevent BPC‑157‑mediated GHR upregulation and downstream ERK/Egr-1 induction, even when HSPGs are intact.
• Exogenous ghrelin will synergize with sub‑effective BPC-157 concentrations to produce a supra‑additive increase in GHR expression, reflecting allosteric potentiation.
• In GHSR‑knockout human tendon fibroblasts (CRISPR‑Cas9), BPC‑157 will fail to activate JAK2/STAT5 or induce angiogenesis‑related genes, despite intact HSPG binding.

Experimental Design

1. Cell model – Primary human tendon fibroblasts (HTFs) cultured in serum‑free medium.
2. Treatments – (a) BPC-157 (0.1–0.5 µg/mL), (b) BPC-157 + heparinase III (1 U/mL), (c) BPC-157 + syndecan‑4 siRNA, (d) BPC-157 + GHSR inverse agonist (1 µM), (e) BPC-157 + ghrelin (100 nM), (f) vehicle controls.
3. Readouts (time‑course) – qPCR for GHR and Egr-1 (15 min, 6 h, 24 h); Western blot for p‑JAK2, p‑STAT5, p‑ERK1/2; nitric oxide assays (Griess) for Nos3/Nos1 vs Nos2; immunofluorescence for syndecan‑4 and GHSR colocalization.
4. Genetic validation – Generate syndecan‑4 KO and GHSR KO HTFs via CRISPR; repeat BPC-157 treatment.
5. Statistical analysis – Two‑way ANOVA with post‑hoc Tukey; n ≥ 3 biological replicates.

Potential Outcomes and Falsifiability

• Supportive outcome: Heparinase or syndecan‑4 loss reduces BPC-157‑induced GHR/Egr-1 by >70%; GHSR blockade mimics this effect; combined BPC-157 + ghrelin yields >2‑fold synergistic GHR rise; KO of GHSR abolishes all downstream signaling.
• Falsifying outcome: Heparinase treatment, syndecan‑4 knockdown, or GHSR antagonism have no significant impact on BPC-157‑mediated GHR upregulation, JAK2 phosphorylation, or Egr-1 induction, indicating that the proposed HSPG‑GHSR axis is not required.

Such a study would directly address the open question of BPC-157’s primary receptor, clarify the translational relevance of rodent GHR/JAK2 data, and provide a mechanistic framework that integrates the fragmented observations of Egr‑1, NO modulation, and angiogenesis into a cohesive signaling model.